Physician profile
Dean A Atkinson
NPI 1700883808
$12,570.64
in general payments reported to CMS, 2019-2025
33 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,687 · 2020: $634 · 2021: $993 · 2022: $1,179 · 2023: $1,615 · 2024: $1,377 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,893 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.42 |
| Education | $184.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $4,070.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,924.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $871.31 | 2019-2025 | Dupixent |
| Genzyme Corporation | $748.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $737.65 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $695.49 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $454.94 | 2019-2025 | |
| Genentech USA, INC. | $445.78 | 2019-2025 | Xolair |
| Pfizer INC. | $346.70 | 2019-2025 | |
| Alk-Abello, INC | $315.95 | 2019-2024 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Takeda Pharmaceuticals U.S.A., INC. | $275.24 | 2021-2025 | Hyqvia, Eohilia, Takhzyro |
| Kaleo, INC. | $259.97 | 2019-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $209.69 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $185.82 | 2020-2024 | |
| Grifols USA, LLC | $178.09 | 2023-2025 | Xembify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $140.53 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $129.48 | 2023-2025 | Ruconest |
| Abbvie INC. | $78.69 | 2022 | |
| Blueprint Medicines Corporation | $61.34 | 2023-2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $59.68 | 2020-2022 | |
| Amgen INC. | $57.76 | 2024-2025 | Tezspire |
| Octapharma USA, INC. | $45.34 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $39.49 | 2023 | Ryaltris |
| Genentech, INC. | $35.00 | 2024 | Xolair |
| Ionis Pharmaceuticals, INC. | $33.90 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $33.70 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $27.69 | 2019 | |
| Dermavant Sciences, INC. | $25.39 | 2024 | Vtama |
| Mylan Specialty L.P. | $22.45 | 2022 | |
| Galderma Laboratories, L.P. | $21.83 | 2025 | Nemluvio |
| Greer Laboratories, INC. | $21.56 | 2022 | |
| Shire North American Group INC | $11.15 | 2019 | |
| Cycle Pharmaceuticals INC | $4.82 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.